Streetbeat News

BVNRY

Bavarian Nordic A/S

http://www.bavarian-nordic.com/

CEO

Paul Chaplin

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

9.01

Mkt cap

2.1B

Volume

32K

High

9.07

P/E Ratio

13.28

52-wk high

14.60

Low

8.97

Div yield

N/A

52-wk low

7.89

The article discusses whether Bavarian Nordic (BVNRY) stock is currently undervalued, focusing on the Zacks Rank system which uses earnings estimates and revisions to identify strong stocks. The analysis also considers value, growth, and momentum trends.

Portfolio Pulse from

November 11, 2024 | 4:00 pm

Bavarian Nordic has received EMA approval to extend the marketing authorization of its Mpox vaccine to adolescents aged 12 to 17. A clinical trial for children aged 2 to 12 is expected to start next month.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:54 pm

The UK government has secured over 150,000 doses of the mpox vaccine from Bavarian Nordic to combat the clade I mpox variant. The vaccines will be distributed by the NHS, prioritizing high-risk individuals. This move is part of a broader effort to address global health emergencies, with significant funding and collaboration with international organizations.

Portfolio Pulse from Vandana Singh

September 17, 2024 | 4:12 pm

Moderna's investigational mpox vaccine, mRNA-1769, shows greater effectiveness than the current Jynneos vaccine in animal studies. The vaccine is in Phase 1/2 trials, with results expected in 2025. BioNTech is also developing a similar vaccine. Moderna's stock is down 1.39%.

Portfolio Pulse from Vandana Singh

September 06, 2024 | 6:02 pm

The Democratic Republic of Congo received its first batch of mpox vaccines, nearly two years after declaring an epidemic. The vaccines, MVA-BN, are produced by Bavarian Nordic A/S and are the only approved mpox vaccines in several regions. The delay in vaccine distribution is attributed to regulatory and logistical challenges.

Portfolio Pulse from Vandana Singh

September 06, 2024 | 2:03 pm

The WHO has announced a $135M strategic plan to combat the mpox outbreak, focusing on vaccination and prevention efforts. Companies like Bavarian Nordic, Emergent Biosolutions, GeoVax Labs, and SIGA Technologies, which are involved in mpox vaccines and treatments, have seen stock volatility.

Portfolio Pulse from Chris Katje

August 26, 2024 | 7:58 pm

Labcorp and Roche are increasing their mpox testing capabilities in response to a new virus strain. Labcorp can scale up from 500 to 25,000 tests monthly, while Roche is leveraging its HIV testing infrastructure. Quest Diagnostics and Abbott Laboratories are also involved in mpox testing.

Portfolio Pulse from Vandana Singh

August 26, 2024 | 5:36 pm

A new mpox variant, Clade I, is causing global concern, with increased screening in Europe and China. The variant is more severe and transmissible, prompting vaccine and drug developments. Bavarian Nordic and SIGA Technologies are key players in the vaccine and treatment landscape.

Portfolio Pulse from Michael Juliano

August 19, 2024 | 6:26 pm

Bavarian Nordic has submitted clinical data to the European Medicines Agency to extend the use of its Imvanex vaccine to adolescents aged 12-17. The vaccine, known as Jynneos in the U.S., is currently approved for adults. The submission is based on a study showing similar immune responses and safety profiles in both adolescents and adults. Bavarian Nordic is also planning a trial for children aged 2-12. The company has a stock of ready-to-ship doses and expects to deliver 2 million doses by the end of the year. Bavarian Nordic's stock rose 15.39% to $14.02.

Portfolio Pulse from Vandana Singh

August 16, 2024 | 2:44 pm

Several healthcare stocks related to mpox are experiencing significant movements after the WHO declared a public health emergency due to an mpox outbreak in Africa. Emergent Biosolutions, Bavarian Nordic, GeoVax Labs, and SIGA Technologies are among the companies affected.

Portfolio Pulse from Adam Eckert

August 15, 2024 | 5:53 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.